BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director George B. Abercrombie sold 5,000 shares of the business’s stock in a transaction dated Thursday, July 15th. The stock was sold at an average price of $15.69, for a total transaction of $78,450.00. Following the completion of the sale, the director now owns 8,000 shares in the company, valued at $125,520. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
NASDAQ BCRX opened at $16.53 on Thursday. BioCryst Pharmaceuticals, Inc. has a 12 month low of $3.30 and a 12 month high of $17.74. The company’s 50-day moving average is $15.69.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Thursday, May 6th. The biotechnology company reported ($0.36) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.10). BioCryst Pharmaceuticals had a negative net margin of 653.70% and a negative return on equity of 5,272.40%. The company had revenue of $19.06 million for the quarter, compared to analyst estimates of $12.80 million. Sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -1.1 earnings per share for the current year.
Several research firms recently commented on BCRX. Needham & Company LLC reiterated a “hold” rating on shares of BioCryst Pharmaceuticals in a research report on Thursday, April 15th. Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday. Cowen boosted their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $21.00 and gave the stock an “outperform” rating in a research report on Thursday, June 17th. Evercore ISI boosted their price objective on shares of BioCryst Pharmaceuticals from $16.00 to $20.00 in a research report on Friday, May 7th. Finally, Piper Sandler boosted their target price on shares of BioCryst Pharmaceuticals from $15.00 to $18.00 and gave the company an “overweight” rating in a research note on Friday, May 28th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. BioCryst Pharmaceuticals presently has an average rating of “Buy” and an average target price of $14.72.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
Further Reading: What is the operating income formula?
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.